Danavorexton - Takeda
Alternative Names: TAK-925Latest Information Update: 26 Feb 2024
At a glance
- Originator Takeda
- Class Cyclohexanes; Esters; Ethers; Piperidines; Sleep disorder therapies; Small molecules; Sulfonamides
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neurological disorders; Sleep apnoea syndrome
- Phase I Narcolepsy; Respiration disorders
- No development reported Idiopathic hypersomnia
Most Recent Events
- 01 Feb 2024 Phase-II clinical trials in Neurological disorders (IV) (Takeda pipeline; February 2024)
- 31 Jul 2023 Danavorexton is still in phase-I trials for Narcolepsy (In adults, In the elderly) in Japan(IV, Injection) (Takeda pipeline; July 2023)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Idiopathic-hypersomnia(In the elderly, In adults) in Japan (IV, Infusion)